LB PHARMACEUTICALS INC
LB Pharmaceuticals is a late-stage biopharmaceutical company developing treatments for neuropsychiatric disorders, including schizophrenia, bipolar depression and major depressive disorder. Its lead product candidate, LB-102, is an oral small molecule in clinical development as an antipsychotic. The company initiated a Phase 3 schizophrenia trial in March 2026 and a Phase 2 trial for bipolar depression in January 2026, and plans a Phase 2 trial evaluating LB-102 as an adjunctive treatment for major depressive disorder. It is also developing a long-acting injectable formulation of LB-102. LB Pharmaceuticals aims to develop LB-102 for additional neuropsychiatric conditions and holds global rights to the candidate. It intends to retain U.S. commercialization rights and expects to commercialize the oral form in jurisdictions where amisulpride is unavailable as a generic if approved for schizophrenia. The company is headquartered in New York.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $LBRX in the last 7 days.
No SEC Form 4 filings for $LBRX in the last 30 days.
See all $LBRX insider activity →LB Pharmaceuticals (LBRX) reported a Q3 GAAP EPS of -$1.79. The company stated it has $403.8M in cash and short-term investments as of September 30, 2026, expected to fund operations beyond Q2 2029.
LB Pharmaceuticals reported Q3 2026 results, appointing new CFO and CMO. The company expects topline data from its Phase 3 NOVA-2 trial of LB-102 in schizophrenia in 1H 2027. It raised $150M in a private placement and has $403.8M in cash, expected to fund operations beyond Q2 2029. LB-102 is in late-stage development for schizophrenia, bipolar depression, and MDD.
LB Pharmaceuticals Inc. is set to report Q3 results with analysts expecting a narrower loss of 99 cents per share. The company has no revenue and faces scrutiny over cash burn. Analysts maintain a Strong Buy consensus with a $58 average price target, citing confidence in its lead drug LB-102 for schizophrenia. Investors will focus on trial progress and cash runway management.
Recent LBRX coverage spans financial news, earnings and technology.
Negative earnings surprise may pressure the stock lower.
The sizable loss and increased R&D spend may weigh on the stock, but the strong cash position and upcoming Phase 3 readout provide upside catalysts.
Near-term earnings and cash runway concerns are likely to dominate, while any incremental Phase 3 execution commentary can swing expectations for the 1H 2027 readout.
Analyst upgrade with a high price target may drive buying interest.
Potential upside as analysts raise targets.
AlphAI scores every news story that mentions LBRX with an AI model for sentiment and relevance, and aggregates insider trades from LB PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
LB Pharmaceuticals (LBRX) reported a Q3 GAAP EPS of -$1.79. The company stated it has $403.8M in cash and short-term investments as of September 30, 2026, expected to fund operations beyond Q2 2029.
LB Pharmaceuticals reported Q3 2026 results, appointing new CFO and CMO. The company expects topline data from its Phase 3 NOVA-2 trial of LB-102 in schizophrenia in 1H 2027. It raised $150M in a private placement and has $403.8M in cash, expected to fund operations beyond Q2 2029. LB-102 is in late-stage development for schizophrenia, bipolar depression, and MDD.
LB Pharmaceuticals Inc. is set to report Q3 results with analysts expecting a narrower loss of 99 cents per share. The company has no revenue and faces scrutiny over cash burn. Analysts maintain a Strong Buy consensus with a $58 average price target, citing confidence in its lead drug LB-102 for schizophrenia. Investors will focus on trial progress and cash runway management.
Guggenheim reiterated its buy rating on LB Pharmaceuticals, citing promising clinical data for its schizophrenia drug LB-102 and potential in mood disorders. The brokerage maintained an $80 price target, implying 102% upside from the stock's $39.64 price. LB-102 showed low EPS rates in Phase 2 trials, with new data suggesting targeted brain activity. Pivotal trial results are expected in early 2027.
Analysts reiterated Buy ratings on SpaceX (SPCX) with a $250.00 target, Six Flags (FUN) with a $17.00 target, and LB Pharmaceuticals (LBRX) with a $53.00 target. Consensus targets suggest 61.5%, 126.6%, and 58.0% upside respectively.
Stifel maintained a Buy rating and $53 price target for LB Pharmaceuticals (LBRX) after meetings with executives. LBRX shares have risen 156% over the past year. The company is preparing for a phase 3 schizophrenia trial readout for LB-102 in 2027. Analysts cite potential market opportunities in schizophrenia and Alzheimer's. LBRX is not expected to be profitable this year, but has a strong financial health rating.
JPMorgan Chase reduced its stake in LB Pharmaceuticals (LBRX) by 95,503 shares at $38.38 each, retaining 1.4M shares. LBRX, a biotech firm, has no revenue and operates at a loss. Its stock is down 11.41% since the trade, currently at $34.00. JPMorgan's remaining stake represents 4.30% of its portfolio.
H.C. Wainwright maintained a Buy rating and $60 price target for LB Pharmaceuticals (LBRX), citing positive preclinical data on LB-102. The stock has gained 141% over the past year but may be overvalued. Other analysts also reiterated Buy ratings with higher price targets, highlighting LB-102's potential in treating neuropsychiatric disorders. LBRX trades at $37.22, offering 61% upside to the $60 target.
Guggenheim reiterated a Buy rating and $80.00 price target on LB Pharmaceuticals (LBRX) after new preclinical study results for LB-102. The stock has risen 141% in the past year to $37.22. The company has more cash than debt. Analysts estimate U.S. peak sales of $2.1B for schizophrenia and $1.3B for bipolar depression. Other analysts also raised price targets and ratings.
LB Pharmaceuticals (LBRX) presented preclinical and clinical data on LB-102 at the ECNP congress. The data showed LB-102's potential to modulate dopamine signaling and improve cognitive performance in schizophrenia. The company also detailed ongoing Phase 3 trials for schizophrenia and a Phase 2 trial for bipolar depression.
